Premium
Potential drug–drug interactions associated with drugs currently proposed for COVID‐19 treatment in patients receiving other treatments
Author(s) -
Lemaitre Florian,
Solas Caroline,
Grégoire Matthieu,
Lagarce Laurence,
Elens Laure,
Polard Elisabeth,
SaintSalvi Béatrice,
Sommet Agnès,
Tod Michel,
BarinLe Guellec Chantal
Publication year - 2020
Publication title -
fundamental and clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.655
H-Index - 73
eISSN - 1472-8206
pISSN - 0767-3981
DOI - 10.1111/fcp.12586
Subject(s) - drug , medicine , covid-19 , intensive care medicine , drug treatment , pharmacotherapy , drug interaction , pharmacology , clinical trial , disease , pathology , outbreak , infectious disease (medical specialty)
Patients with COVID‐19 are sometimes already being treated for one or more other chronic conditions, especially if they are elderly. Introducing a treatment against COVID‐19, either on an outpatient basis or during hospitalization for more severe cases, raises the question of potential drug–drug interactions. Here, we analyzed the potential or proven risk of the co‐administration of drugs used for the most common chronic diseases and those currently offered as treatment or undergoing therapeutic trials for COVID‐19. Practical recommendations are offered, where possible.